Answers are grounded in this paper and cite their sources.
To the Editor: Accurate assessment of medical-care costs associated with HIV disease and AIDS is necessary to forecast the economic consequences of the HIV pandemic and to evaluate the economic efficiency of prevention programs and treatment protocols. A recent issue of this journal contained two important contributions to the literature on lifetime HIV/AIDS-related costs. In the first, Gable et al.(1) provided updated estimates of lifetime treatment costs stratified by stage of disease (CD4+ counts). Projected lifetime costs, from seroconversion until death, were estimated at about $95,000 (1995 dollars). In the second article, Hurley et al.(2) used HIV-related health care costs for homosexual men in Australia to estimate the total treatment costs for each stage of disease. This study also highlighted the importance of discounting future costs and benefits to their present values as well as making explicit assumptions regarding when HIV-infected individuals first access the health care system. The purpose of the present letter is to provide a bridge between the Gable et al. and Hurley et al. articles and to extend the analyses contained therein. Present value adjustments to costs and benefits incurred in the future are necessary to reflect the increased value of resources available in the present as opposed to the future, independent of inflationary concerns (such resources could be invested to increase future net value, for example). Both the Centers for Disease Control and Prevention (CDC) guidelines(3) and the recently released report of the U.S. Public Health Service Panel on Cost-Effectiveness(4) recommend discounting at a standard 3% annual rate, with other rates (e.g., 0 and 5%) examined in sensitivity analyses. Discounting Gable et al.'s estimates at 3 and 5% results in revised lifetime cost estimates of about$71,000 and $59,000, respectively, the latter of which is quite similar to the $56,000 estimate reported previously by other researchers(5). Discounting future costs to present value can thus make a substantial difference in the estimates obtained (use of a 5% discount rate reduces cost estimates by nearly 40%). When forecasting future expenditures for HIV/AIDS care, it is also important to consider the stage of disease progression at which HIV-infected individuals access the health care system. One of the key economic benefits of preventing someone from becoming infected with HIV is the large savings in medical-care costs, but the amount of this savings depends on when the individual would have begun treatment had he or she become infected. The limited available evidence suggests that many people are first diagnosed as HIV-positive relatively late in the disease(6). Although late access to treatment reduces expected health care costs, discounting somewhat limits the extent of this reduction(2), as illustrated in Fig. 1, which shows the expected lifetime cost, discounted to the time of seroconversion, of HIV/AIDS medical care as a function of the number of years past seroconversion in which treatment is initiated. (This analysis assumes the 12.4-year course of HIV disease reported by Hellinger(7) and used in the Gable et al. paper.) Thus, although medical care costs incurred in the last 3 years of life account for about 65% of the undiscounted total, discounting at a 3 or 5% rate reduces this proportion to about 55%.FIG. 1.: Lifetime HIV/AIDS treatment costs as a function of the number of years between seroconversion and first access of health care system for three discount rates (0, 3, and 5%).As the figure makes clear, the ultimate cost of HIV/AIDS care differs greatly, depending on the stage of disease progression when treatment is initiated. This effect is likely to become even more pronounced with the development and use of more effective, and more costly, early antiretroviral therapies, including protease inhibitor/nucleoside analog combinations. Moreover, as infected people live longer, medical-care costs expended during the final stages of AIDS will decrease as a proportion of overall costs. Attention to matters of discounting and access to care are necessary to ensure accurate assessment of the true costs of HIV/AIDS. Due to uncertainty in this area, analysts should conduct sensitivity analyses using a range of lifetime medical-care cost estimates(3,4). Because HIV/AIDS-related costs are fluid, it is important to have up-to-date estimates available to ensure that economic analyses remain as current as possible. Gable, Hurley, and their colleagues are to be commended for their efforts in this area. Acknowledgment: This research was supported in part by grants R01-MH55440 and P30-MH52776 from the National Institute of Mental Health. Steven D. Pinkerton David R.
No takes yet. Share an insight, caveat, or question.
Pinkerton et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: